These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
803 related articles for article (PubMed ID: 15709216)
21. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B; Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635 [TBL] [Abstract][Full Text] [Related]
22. Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor. Hernàndez DE; Hernàndez AE Eur J Cancer Care (Engl); 2006 Dec; 15(5):493-6. PubMed ID: 17177909 [TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype. Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583 [TBL] [Abstract][Full Text] [Related]
24. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI J Clin Oncol; 2004 Nov; 22(21):4302-11. PubMed ID: 15381684 [TBL] [Abstract][Full Text] [Related]
25. Dose-intensive chemotherapy with cisplatin, vincristine, doxorubicin and etoposide against lung cancer: a pilot study. Yanagawa H; Bando H; Takishita Y Anticancer Res; 1995; 15(2):613-6. PubMed ID: 7539241 [TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472 [TBL] [Abstract][Full Text] [Related]
27. New treatment strategies for aggressive lymphoma. Younes A Semin Oncol; 2004 Dec; 31(6 Suppl 15):10-3. PubMed ID: 15726533 [TBL] [Abstract][Full Text] [Related]
28. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005 [TBL] [Abstract][Full Text] [Related]
29. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M; Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026 [TBL] [Abstract][Full Text] [Related]
30. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma]. Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071 [TBL] [Abstract][Full Text] [Related]
31. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. Engert A; Bredenfeld H; Döhner H; Ho AD; Schmitz N; Berger D; Bacon P; Skacel T; Easton V; Diehl V Haematologica; 2006 Apr; 91(4):546-9. PubMed ID: 16585019 [TBL] [Abstract][Full Text] [Related]
32. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437 [TBL] [Abstract][Full Text] [Related]
34. [Study of optimal CHOP dose ranges for elderly patients with non-Hodgkin's lymphoma]. Mori M; Murai Y; Suzuki K; Nonaka Y; Sato H; Tomiyama J; Takagi T; Muto Y; Kashimura M Rinsho Ketsueki; 1999 Mar; 40(3):199-204. PubMed ID: 10222626 [TBL] [Abstract][Full Text] [Related]
35. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671 [TBL] [Abstract][Full Text] [Related]
36. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma]. Hou M; Li L; Qiu M; Yan X; Zhu J; Gou HF Ai Zheng; 2005 Apr; 24(4):461-4. PubMed ID: 15820070 [TBL] [Abstract][Full Text] [Related]
37. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Picozzi VJ; Pohlman BL; Morrison VA; Lawless GD; Lee MW; Kerr RO; Ford JM; Delgado DJ; Fridman M; Carter WB Oncology (Williston Park); 2001 Oct; 15(10):1296-306; discussion 1310-1, 1314. PubMed ID: 11702959 [TBL] [Abstract][Full Text] [Related]
38. Frequency and severity of neutropenia in diffuse large B-cell non Hodgkin's lymphoma after first cycle of chemotherapy comprising cyclophosphamide, doxorubicin, vincristine with prednisolone. Nadeem M; Idrees M; Khattak J; Hussain I; Amin Z; Arif S; Zeeshan M; Hussain M J Ayub Med Coll Abbottabad; 2011; 23(1):80-3. PubMed ID: 22830154 [TBL] [Abstract][Full Text] [Related]
39. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer. Miller AA; Al Omari A; Murry DJ; Case D Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403 [TBL] [Abstract][Full Text] [Related]
40. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Dann EJ; Epelbaum R; Avivi I; Ben Shahar M; Haim N; Rowe JM; Blumenfeld Z Hum Reprod; 2005 Aug; 20(8):2247-9. PubMed ID: 15817583 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]